🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524868-38-00
Authorised Phase I

A Phase 1b Study of ZN-c3 in Combination with Chemotherapy or Bevacizumab in Subjects with Ovarian, Peritoneal, or Fallopian Tube Cancer

2025-524868-38-00 · tracked via the Priya Life Science EU tracker
Sponsor
K-Group Beta Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
13/08/2026
Enrollment target
40
Sites
France

Condition studied

Ovarian, Peritoneal, or Fallopian Tube Cancer

Eligibility

Age group
18-64 years, 65+ years
Sex
Female
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524868-38-00 on CTIS ↗ ← All trials in the EU